Business Wire

HENLEY-&-PARTNERS

28.10.2020 12:30:10 CET | Business Wire | Press release

Share
Australia’s Global Talent Visa Program Sees Tech CEOs Swap Silicon Valley for Sydney

Australia’s Global Talent Visa Program, also known as the Global Talent Independent Program, is making waves across the Pacific, attracting dynamic, high-profile business leaders to the country’s shores, with many hailing from the US. The program is fine tuned to attract only the world’s premium business talent, and this highly targeted approach has proven to be a great success as clients include top Palo Alto executives and leading Tech CEOs.

The program is aimed at highly skilled individuals and high-income earners and was expressly designed to grow Australia’s innovation and tech economies. The seven future-focused target sectors: AgTech, Space and Advanced Manufacturing, FinTech, Energy and Mining Technology, MedTech, Cyber Security, and Quantum Information, Advanced Digital, Data Science and ICT. With no age limit or investment prerequisite, the only requirements for applicants are to be internationally recognized, prominent in their field, and able to provide evidence of outstanding achievements. There are 15,000 places available in 2020–2021, and successful applicants can obtain fast-tracked permanent residence for the whole family within six weeks and have a full five years to make the move Down Under. Places are also available to internationally recognized master’s and PhD students who can demonstrate their exceptional talent.

Director of leading international citizenship and residence advisory firm Henley & Partners’ Australia office, Tony Le Nevez , says the country’s prosperity, safety, and excellent quality of life make it a highly sought-after destination for high-net-worth individuals and entrepreneurs. “Stimulating innovation — and tech innovation in particular — should be a non-negotiable for any sovereign state in the current context. By attracting and harnessing the world’s cutting-edge talent, Australia’s permanent residence offering will ensure that the country stays well ahead of the game. The coronavirus-related events of 2020 have provoked a desire for change, leading many individuals to seek out alternative options. We have seen a huge spike globally in interest in investment migration programs, and from Americans in particular. The Global Talent Visa Program presents a perfect opportunity for matching top global talent with a safe, reliable, and successful country that is forward looking.”

Dominic Volek , Henley & Partners Group Head of Private Clients, says “Contrary to what many believe, residence and citizenship programs are not the exclusive domain of nations that are struggling economically or starved of foreign capital. Nineteen of the Group of 20 nations, including the UK and the US, offer a mechanism to attract inward investment in exchange for residence rights. Sixty percent of EU member states offer investment migration programs. These highly developed nations design and implement these programs for the same reasons small and developing nations do — to attract foreign capital, skills, and knowledge to stimulate their domestic economies.”

For successful HNWI who might not be the next Steve Jobs, Australia offers various pathways to permanent residence. Under the Skilled – Investment/Entrepreneurial program there are six main streams for business innovators, investors, significant investors, entrepreneurs, business talent, and venture capitalist entrepreneurs, with minimum requirements ranging from business turnover of AUD 500,000 and net assets of AUD 800,000 (Business Innovation stream) to committing at least AUD 5 million into a complying Australian investment for at least four years (Significant Investor stream). If Australia appeals, it is advisable to apply in the next six to eight months, as significant changes are on the horizon with an announcement expected in July 2021.

Social Media:

https://www.facebook.com/HenleyPartners/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye